215 related articles for article (PubMed ID: 32671653)
1. Correlation of ThyroSeq Results with Surgical Histopathology in Cytologically Indeterminate Thyroid Nodules.
Chin PD; Zhu CY; Sajed DP; Fishbein GA; Yeh MW; Leung AM; Livhits MJ
Endocr Pathol; 2020 Dec; 31(4):377-384. PubMed ID: 32671653
[TBL] [Abstract][Full Text] [Related]
2. Molecular testing for indeterminate thyroid nodules: Performance of the Afirma gene expression classifier and ThyroSeq panel.
Jug RC; Datto MB; Jiang XS
Cancer Cytopathol; 2018 Jul; 126(7):471-480. PubMed ID: 29637728
[TBL] [Abstract][Full Text] [Related]
3. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
Witt RL
Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
[TBL] [Abstract][Full Text] [Related]
4. Interinstitutional variation in predictive value of the ThyroSeq v2 genomic classifier for cytologically indeterminate thyroid nodules.
Marcadis AR; Valderrabano P; Ho AS; Tepe J; Swartzwelder CE; Byrd S; Sacks WL; Untch BR; Shaha AR; Xu B; Lin O; Ghossein RA; Wong RJ; Marti JL; Morris LGT
Surgery; 2019 Jan; 165(1):17-24. PubMed ID: 30360906
[TBL] [Abstract][Full Text] [Related]
5. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay.
Nikiforov YE; Carty SE; Chiosea SI; Coyne C; Duvvuri U; Ferris RL; Gooding WE; Hodak SP; LeBeau SO; Ohori NP; Seethala RR; Tublin ME; Yip L; Nikiforova MN
Cancer; 2014 Dec; 120(23):3627-34. PubMed ID: 25209362
[TBL] [Abstract][Full Text] [Related]
6. Preoperative Role of RAS or BRAF K601E in the Guidance of Surgery for Indeterminate Thyroid Nodules.
Ravella L; Lopez J; Descotes F; Giai J; Lapras V; Denier ML; Borson-Chazot F; Lifante JC; Decaussin-Petrucci M
World J Surg; 2020 Jul; 44(7):2264-2271. PubMed ID: 32227276
[TBL] [Abstract][Full Text] [Related]
7. High-risk and intermediate-high-risk results from the ThyroSeq v2 and v3 thyroid genomic classifier are associated with neoplasia: Independent performance assessment at an academic institution.
Jug R; Foo WC; Jones C; Ahmadi S; Jiang XS
Cancer Cytopathol; 2020 Aug; 128(8):563-569. PubMed ID: 32339438
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Preoperative Molecular Testing and Implications for Initial Surgical Management in Thyroid Nodules Harboring Suspected (Bethesda V) or Known (Bethesda VI) Papillary Thyroid Cancer.
Schumm MA; Shu ML; Hughes EG; Nikiforov YE; Nikiforova MN; Wald AI; Lechner MG; Tseng CH; Sajed DP; Wu JX; Yeh MW; Livhits MJ
JAMA Otolaryngol Head Neck Surg; 2023 Aug; 149(8):735-742. PubMed ID: 37382944
[TBL] [Abstract][Full Text] [Related]
9. Utilities of
Guan H; Toraldo G; Cerda S; Godley FA; Rao SR; McAneny D; Doherty G; Braverman L; Lee SL
Thyroid; 2020 Apr; 30(4):536-547. PubMed ID: 31996097
[No Abstract] [Full Text] [Related]
10. Impact of a genomic classifier on indeterminate thyroid nodules: an institutional experience.
Abdelhakam DA; Mojica RE; Huenerberg KA; Nassar A
J Am Soc Cytopathol; 2021; 10(2):155-163. PubMed ID: 33067175
[TBL] [Abstract][Full Text] [Related]
11. The role of ThyroSeq V3 testing in the management of patients with indeterminate thyroid nodules on fine needle aspiration.
Selvaggi SM
Diagn Cytopathol; 2021 Jul; 49(7):838-841. PubMed ID: 33864719
[TBL] [Abstract][Full Text] [Related]
12. Clinical performance of a next-generation sequencing assay (ThyroSeq v2) in the evaluation of indeterminate thyroid nodules.
Taye A; Gurciullo D; Miles BA; Gupta A; Owen RP; Inabnet WB; Beyda JN; Marti JL
Surgery; 2018 Jan; 163(1):97-103. PubMed ID: 29154079
[TBL] [Abstract][Full Text] [Related]
13. ThyroSeq
Rivas AM; Nassar A; Zhang J; Casler JD; Chindris AM; Smallridge R; Bernet V
Endocr Pract; 2018 Sep; 24(9):780-788. PubMed ID: 30084677
[TBL] [Abstract][Full Text] [Related]
14. Repeat Fine Needle Aspiration Cytology Refines the Selection of Thyroid Nodules for Afirma Gene Expression Classifier Testing.
Nishino M; Mateo R; Kilim H; Feldman A; Elliott A; Shen C; Hasselgren PO; Wang H; Hartzband P; Hennessey JV
Thyroid; 2021 Aug; 31(8):1253-1263. PubMed ID: 33813868
[No Abstract] [Full Text] [Related]
15. The histologic outcomes of indeterminate thyroid nodules with rat sarcoma mutations: A case series.
Jones M; Abendano DG; Turner M; Sullivan C; Reyes MCD
Diagn Cytopathol; 2023 Dec; 51(12):E332-E337. PubMed ID: 37583345
[TBL] [Abstract][Full Text] [Related]
16. Young Investigator Challenge: Molecular testing in noninvasive follicular thyroid neoplasm with papillary-like nuclear features.
Jiang XS; Harrison GP; Datto MB
Cancer Cytopathol; 2016 Dec; 124(12):893-900. PubMed ID: 27893191
[TBL] [Abstract][Full Text] [Related]
17. Analytical performance of the ThyroSeq v3 genomic classifier for cancer diagnosis in thyroid nodules.
Nikiforova MN; Mercurio S; Wald AI; Barbi de Moura M; Callenberg K; Santana-Santos L; Gooding WE; Yip L; Ferris RL; Nikiforov YE
Cancer; 2018 Apr; 124(8):1682-1690. PubMed ID: 29345728
[TBL] [Abstract][Full Text] [Related]
18. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma.
An JH; Song KH; Kim SK; Park KS; Yoo YB; Yang JH; Hwang TS; Kim DL
Clin Endocrinol (Oxf); 2015 May; 82(5):760-6. PubMed ID: 25109485
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytology.
Valderrabano P; Khazai L; Leon ME; Thompson ZJ; Ma Z; Chung CH; Hallanger-Johnson JE; Otto KJ; Rogers KD; Centeno BA; McIver B
Endocr Relat Cancer; 2017 Mar; 24(3):127-136. PubMed ID: 28104680
[TBL] [Abstract][Full Text] [Related]
20. ThyroSeq v3 for Bethesda III and IV: An institutional experience.
Desai D; Lepe M; Baloch ZW; Mandel SJ
Cancer Cytopathol; 2021 Feb; 129(2):164-170. PubMed ID: 33030808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]